Atlas Trials

Akero Therapeutics, Inc

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Akero Therapeutics, Inc

RecordFirmDate
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH (NCT06528314)Akero Therapeutics, Inc2024-09-04
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis (NCT06215716)Akero Therapeutics, Inc2023-12-01
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (NCT06161571)Akero Therapeutics, Inc2023-11-10
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry) (NCT05039450)Akero Therapeutics, Inc2021-07-30
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (NCT04767529)Akero Therapeutics, Inc2021-02-16
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (NCT03976401)Akero Therapeutics, Inc2019-05-28

Track Akero Therapeutics, Inc automatically

Every clearance here is in the API, with alerts when new ones post.